Research

Analysis: Cure SMA’s Risk/Benefit Survey

December 20, 2023
Posted in , ,

One of Cure SMA’s top priorities is to relay the SMA community’s treatment experiences and preferences to the United States Food and Drug Administration (FDA). […]

Read More ›

Identifying Biomarkers of Spinal Muscular Atrophy for Further Development

September 28, 2023
Posted in ,

An important part of Cure SMA’s core mission is to carry out and support research that will improve the quality of life for all people […]

Read More ›

Biohaven Completes Enrollment in Pivotal Phase 3 Study

September 19, 2023
Posted in , , ,

Recently, Biohaven released a statement on the completed enrollment of their pivotal Phase 3 Study of Taldefgrobep Alfa in people with SMA. Check out Biohaven’s […]

Read More ›

Clinical Research and Drug Development Session Highlights from 2023 SMA Research & Clinical Care Meeting

August 7, 2023
Posted in , ,

At the end of June, SMA researchers and clinicians from around the world met in Orlando, Florida, for the 2023 Annual SMA Research & Clinical […]

Read More ›

Cure SMA Announces Expanded Phase 3 of Real World Evidence Collaboration

July 31, 2023
Posted in ,

Cure SMA is pleased to announce the launch of an expanded Phase 3 of the Real World Evidence Collaboration. The collaboration was established to leverage […]

Read More ›

SMA Scientists and Clinicians from Around the World Gather at the 27th Annual SMA Research & Clinical Care Meeting

July 26, 2023
Posted in , ,

At the end of June, SMA researchers and clinicians from around the world met in Orlando, Florida, for the 2023 Annual SMA Research & Clinical […]

Read More ›

Cure SMA’s 2022 State of SMA Report

July 12, 2023
Posted in , ,

Cure SMA is pleased to announce the launch of the second annual State of SMA report. The purpose of this report is to share highlights […]

Read More ›

Cure SMA Awards $100,000 Grant to Saravanan Arumugam, PhD, Universidad de Seville

April 5, 2023
Posted in , ,

Saravanan Arumugam, PhD, was awarded $100,000 for his research project, “Role of Cytosolic and Mitochondrial Ca2+ in the Pathogenesis of Spinal Muscular Atrophy.” Dr. Arumugam’s […]

Read More ›

Cure SMA Awards $75,000 Grant to Lyndsay Murray, PhD, University of Edinburgh

March 20, 2023
Posted in ,

Lyndsay Murray, PhD, was awarded $75,000 for her research project, “Evaluating the impact of sequential versus simultaneous administration of SMN-inducing compounds on motor unit recovery […]

Read More ›

Biohaven’s Taldefgrobep Alfa Receives FDA Fast Track Designation for Spinal Muscular Atrophy

February 24, 2023
Posted in , ,

This week, Biohaven announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for taldefgrobep alfa, a novel anti-myostatin adnectin, […]

Read More ›
Scroll to Top